Status:
TERMINATED
ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment
Lead Sponsor:
elbion AG
Conditions:
Panic Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study is designed to investigate if 600 mg ELB139 given orally t.i.d. to patients suffering from panic disorder is effective in reducing anxiety evoked by inhalation of 35% CO2 measured by a visu...
Eligibility Criteria
Inclusion
- Diagnosis of concurrent panic disorder
- At least 2 panic attacks within the 4 weeks before the screening visit
- Naïve to the CO2 challenge test
- Age 18-65 years (inclusive)
- Ability to comply with all procedures mandated by the study protocol
- Negative pregnancy test and adequate contraceptive measures
Exclusion
- History of poly-pharmacotherapy for panic disorder or treatment resistance
- Any current psychiatric Axis I DSM-IV diagnosis other than panic disorder, except concurrent simple phobia
- History of abuse of benzodiazepines or tolerance to effects of benzodiazepine
- Any concomitant psychotropic medication
- Evidence of impaired hepatic, renal or cardiac functions
- Participation in any drug trial in the preceding 6 months
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00322803
Start Date
May 1 2006
End Date
October 1 2006
Last Update
September 29 2006
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité - University Clinics Berlin
Berlin, Germany, 10117
2
Emovis, The institute of emotional health
Berlin, Germany, 10629
3
Academic Anxiety Center and Department of Psychiatry & Neuropsychology; Maastricht University
Maastricht, Netherlands, 6200 MD